To examine the relationship between plasma homocysteine, 5,10-methylenetetrahydrofolate reductase (MTHFR) polymorphism. and the risk of arterial and/or venous thrombosis in systemic lupus erythematosus (SLE).
Plasma homocysteine and MTHFR polymorphism were determined in a retrospective cohort of 175 patients with SLE.
Associations between homocysteine levels and antiphospholipid antibodies. renal function, and drug therapy were analyzed.
Patients with arterial thrombosis had higher homocysteine concentration than nonthrombotic patients (20.6 ± 10.2 VS 13.2 ± 6.8 mumol/l ; p<0.001).
The crude odds ratio for arterial thrombosis for the highest versus lowest quartile of homocysteine was 4.4 (95% Cl 1.3-14.9).
After adjustment for other risk factors the odds ratio remained significant (3.7 ; 95% Cl 1.2-13.0).
Increased plasma homocysteine was not associated with venous thrombosis.
A significant correlation was found between homocysteine and crcatinine (r=0.57. p<0.0001) or the use of methotrexate.
Homocysteine levels were higher in patients using corticosteroids and lower in patients using oral contraceptive drugs.
This finding may be biased by impaired renal function in patients using corticosteroids and the advice to stop estrogen-containing contraceptives in female patients upon an episode of thrombosis.
The distribution of MTHFR genotypes was 50% for homozygous wild type. (...)
Mots-clés Pascal : Lupus érythémateux, Disséminé, Pathogénie, Antiphospholipide syndrome, Plasma, Homocystéine, Thromboembolie, Methylenetetrahydrofolate reductase (NADPH), Oxidoreductases, Enzyme, Polymorphisme, Epidémiologie, Homme, Thrombocyte, Peau pathologie, Tissu conjonctif pathologie, Maladie système, Maladie autoimmune, Immunopathologie, Appareil circulatoire pathologie, Vaisseau sanguin pathologie, Hémopathie, Artère pathologie, Veine pathologie
Mots-clés Pascal anglais : Lupus erythematosus, Disseminated, Pathogenesis, Antiphospholipid antibody syndrome, Plasma, Thromboembolism, Methylenetetrahydrofolate reductase (NADPH), Oxidoreductases, Enzyme, Polymorphism, Epidemiology, Human, Platelet, Skin disease, Connective tissue disease, Systemic disease, Autoimmune disease, Immunopathology, Cardiovascular disease, Vascular disease, Hemopathy, Arterial disease, Venous disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0430936
Code Inist : 002B07. Création : 25/01/1999.